Stockreport

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

Spyre Therapeutics, Inc.  (SYRE) 
PDF WALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and [Read more]